Corindus Vascular Robotics (CVRS) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Corindus Vascular Robotics (CVRS) PT Raised to $2.25 at Cowen
March 15, 2018 6:32 AM EDTCowen raised its price target on Corindus Vascular Robotics (NYSE: CVRS) to $2.25 (from $1.75) while maintaining an Outperform rating.
Analyst Joshua Jennings with another quarter of sequential progress in the commercial launch of CorPath, we continue to view CVRS as a differentiated cardiovascular... More
